updat forecast estim oct
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research oct
estim oct
price data oct
rate updat oct
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
smallest youngest three lead
pharmaceut medic distributor
employe across own oper facil leas
oper facil around world cardin health
address comprehens sourc distribut need
manufactur provid global scale sheer
pharmaceut volum enabl compani negoti
competit price manufactur pharmaci
provid pbm effici provid access vast
portfolio drug core busi roughli revenu
focus pharmaceut distribut balanc
revenu contract manufactur distribut medic
suppli handl roughli one third drug
sold unit state compani oper effici
highli regul environ provid insul
drug price drug mix gener versu brand drug volum
larg drive core busi pharmaceut distribut
servic deceler pharmaceut drug growth due
slower brand drug inflat shift mix favor gener
drug lower price point slower introduct blockbust
drug increas provid negoti leverag custom
concentr put oper margin pressur
howev high cost pharmaceut drug off-set
declin introduct brand drug overal
oper margin rel displac brand drug like
lower similar two largest distributor compani
grown signific size regular acquisit
like necessari supplement growth order off-set
slower growth
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
cardin health third-largest global logist provid engag
wholesal pharmaceut medic product similar two
peer compani evolv time becom entrench
sourc distribut brand-nam gener pharmaceut
relat servic hospit healthcar system pharmaci
ambulatori surgeri center clinic laboratori physician offic
acquisit cardin health abil manufactur
commod product certain medic devic
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
month suspens wall street journal report
settlement involv payment billion three
major pharmaceut distributor time
period although term defend particip
appear fluid landmark settlement ahead
oct feder court kick surpris public
pharmaceut suppli compani want distanc
highli charg polit matter
remov largest overhang respect share
summar aug note decade-old
content pharmaceut suppli chain
culmin standoff ohio feder court
lawsuit repres state citi
counti accus drug manufactur activ market
addict drug pharmaceut distributor fail
detect/report suspici opioid order mani
defend case gener drug manufactur
pharmaceut distributor retail pharmaci
coverag drug manufactur spend signific dollar
market brand drug like crux civil
case unlik brand drug gener significantli
cheaper formul sold base price
activ market result think gener
manufactur face lower penalti settl
rel smaller amount brand opioid
indic previous believ settlement
would requir up-front payment dollar services/
product rather could spread multipl year
think make potenti settlement
manag compani coverag
factor smaller payment shorter time period
may modestli adjust fair valu estim revisit
sensit firm settlement figur releas
howev expect impact on-going oper
moat rate
lower fair valu estim cardin health
per share impli fiscal
enterpris adjust ev/ebitda multipl time
free cash flow yield dividend yield
revenu driver price volum mix
disclos made sever assumpt project
industri growth except potenti extern
market shock anticip market share shift
dramat near term result anticip
overal annual top-lin growth roughli larg
benefit growth specialti pipelin
increas number therapi age popul
brand drug
compon growth varieti factor includ
slower growth introduct new
drug neg less extent gener deflat
lower spend hepat prescript opioid
factor net anticip industri revenu
growth roughli similar industri
rang accord iqvia express script
consist overal pharmaceut spend trend
expect revenu grow declin
approxim compound-annual-growth-rate past three year
histor revenu growth continu lumpi due
mix drug introduct inflat acquisit
overal drug volum skew toward gener similar
industri averag roughli howev lower
gener price point would translat roughli half
optumrx top five custom account
approxim total consolid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
base scenario per share
bull-cas fair valu estim per share
scenario revenu growth basi
point higher base scenario result slightli
bear-cas fair valu estim per share
oper margin project declin basi
point due increas custom
negoti leverag signific chang
legisl regulatori environ extern shock
factor would increas uncertainti
uncertainti rate pharmaceut
distributor stand medium due competit
environ potenti extern shock includ
legisl chang increas price transpar
potenti entranc new competitor
cardin assign narrow-moat rate aris
cost advantag
cardin health
effect oper oligopoli entrench
within custom base three lead distributor
similar differ slightli largest
pharmaceut distributor certain global contract
manufactur capabl vertic integr
provid retail pharmaci chain canada
europ closest pure-play
pharmaceut distributor platform base insid
close provid retail pharmaci cardin
smallest three lead pharmaci
distributor
manufactur capabl medic devic
past three four year oper margin
industri declin oper margin cardin
declin
model oper margin declin
fiscal next five year declin
revenu anticip continu pressur
pharmaceut distribut headwind
ration medic devic oper
part valuat framework addit
base-cas dcf model bull case bear case
valuat scenario critic debat
surround compani abil entrench exist
partnership manufactur
negoti provid
financ
inventori manag servic
provid negoti provid specialti drug distribut
base current high level custom concentr
increas competit environ potenti
regulatori chang believ limit upsid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
compani invest infrastructur provid
abil navig highli regul drug market scale
also enabl compani negoti behalf
provid retail pharmaci requir infrastructur
regulatori hurdl requir logist manag
insul compani new entrant
divis baxter healthcar medic devic
compani divis johnson johnson medtron
addit sever smaller acquisit also unlik
cardin
certain contract manufactur acquisit
distributor world along
repres market
time role pharmaceut distributor evolv
increas number new therapi format
govern regulatori organ regulatori
requir
licensur manufactur retail
pharmaci pharmaceut distributor
evolut compani continu invest
physic infrastructur provid logist support
highli effici manner compani scale also
provid abil negoti lower price drug
manufactur across comprehens portfolio gener
brand specialti drug behalf provid acut
hospit clinic mail pharmaci retail
complianc certain financ function provid
manufactur support commerci
infrastructur escal past decad
cardin health invest nearli billion
capit expenditur billion acquisit
billion order strengthen posit matur
autom
cardin health initi found food
focus wholesal drug
manufactur acquisit bailey drug later
decad sinc time compani made seri
acquisit rang autom pill dispens
pyxi medic product manufactur distributor
product distribut limit transport asset
commod natur compani distribut servic
reflect low oper margin despit
low margin compani histor gener roic
larg due scale growth driven strong
drug price inflat increas therapi
current lack price transpar signific
variat list invoic price day day
price volatil regulatori complianc recal
provid retail pharmaci
infrastructur quickli manag avail inform
negoti competit price manufactur
cardin healthss volum also provid abil
lower price drug manufactur
increment scale compani abil provid
assist inventori manag complianc
financ convers compani also support
commerci new drug deliveri product
secur moat scale
uncertain drug price environ grow
custom leverag limit moat narrow recent
howev pharmaceut revenu declin
slower inflat shift revenu mix increas
gener versu brand drug meanwhil margin
declin like part due increas negoti
leverag custom driven healthcar provid
consolid top five custom
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
specif opportunist enter
medic devic busi acquisit cordi
sinc acquisit compani ration
product offer exit roughli countri cardin
continu expand new area maintain
lead posit off-set declin core busi
execut regulatori risk increas concern
addit extern shock highli contest
reduct rebat increas price transpar
would diminish pharmaceut distributor
valu negoti transpar price
provid manufactur would less like need middl
man negoti rate would give custom
leverag renegoti distribut contract
amazon may immedi threat next sever
year discount altogeth
compani signific resourc appear
method gather expertis effect compet
healthcar distribut amazon signific inventori
manag expertis quietli accumul
core piec need compet pharmaceut
distributor includ pillpak state distributor licens
joint ventur jp morgan berkshir
repres revenu oper margin declin
exacerb ratino product
intern locat medic devic acquisit
factor weigh roic trend like
persist long term view
despit insul provid compani amass
physic infrastructur complex regulatori
environ overal market pressur continu build
larg due declin reimburs healthcar
consolid deceler growth
overal
pressur manufactur provid press focu
cost contain result pharmaceut
distribut client activ solicit bid
negoti better price commod servic
distributor also includ client gener sourc
joint ventur red oak sourc cardin
walgreen boot allianc walgreen
claruson
healthcar consolid also increas
concentr pharmaceut distribut custom
top five cardin custom repres
roughli revenu market pressur
leverag pharmaceut distributor
custom
largest contributor
deterior overal industri margin
declin consecut last sever year even
provid manufactur appear test direct
altern may limit could also
like
signific declin pharmaceut market
growth caus distributor seek altern
channel acquisit entri new
area outsid core compet proven costli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
key drug distributor handl
third pharmaceut distribut market
compani infrastructur provid scale abil
effect negoti price provid
inventori
oth compani servic enabl provid
manufactur focu core busi
outsourc logist drug highli
requir high sunk cost low oper margin
provid barrier entri highli matur market
leverag
declin reimburs matur market could
limit futur growth put pressur profit
compani continu make acquisit
outsid core compet seek altern
channel growth execut regulatori risk
oextern shock potenti legisl action
increas drug price transpar entranc
disrupt competitor could disrupt current
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
believ cardin health enjoy posit solid
financi strength aris strong balanc sheet
posit matur market fiscal
compani billion cash equival off-set
billion debt debt capit ratio gross
leverag time adjust ebitda free cash flow
gener million billion fiscal
exclud acquisit respect compar
lead pharmaceut distributor cardin
disciplin acquisit dividend strategi
compani regularli complet acquisit seek new
channel fuel growth manag spent roughli
billion averag acquisit three
fiscal year repres doubl histor trend
annual common stock dividend averag million
past year acceler million
fiscal dividend yield
repurchas billion worth stock fiscal
fiscal million buyback fiscal
manag roughli billion remain
share repurchas author believ compani
continu repurchas share exist
author beyond
compani oper matur oligopoli loss
regulatori chang entrant new competitor
signific resourc overal market dynam could
reduc abil negoti drug manufactur
and/or custom continu pressur drug price
pose risk compani includ deflat gener
drug price increas gener mix slower growth
pharmaci pipelin lower spend hepat
opioid risk could eman propos govern
rule seek increas transpar drug price
elimin rebat pbm propos regulatori
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
chang would reduc cost drug current
pass-through revenu basi pharmaci
wholesal compens although pharmaci
distributor would opportun negoti
drugmak provid uncertainti abil
negoti industri rate paid current
increas transpar continu consolid
retail pharmaci could impact compani abil
negoti lower price cornerston servic
render compani although potenti threat
new competitor immin amazon compani
signific inventori manag expertis
quietli accumul core piec need compet
pharmaceut distributor
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
new york mellon corp
share
fund
share
fund
scott barnhart presid global manufactur
suppli chain join compani last year
presid global suppli chain group purchas
organ respons
suppli chain procur global countri
compani oper profession servic facil
busi prior join barnhart respons
intern suppli chain manufactur
conagra food held rang role span
london-bas diageo plc lead custom servic
plan manufactur procur distributor
oper north america latin america
move corpor posit suppli chain
inform technolog consult pricewaterhousecoop
steve blazejewski presid medic solut
medic product suppli chain servic hospit
laboratori physician offic surgeri center
site care blazejewski join august
compani acquir patient
recoveri busi instrument facilit
purchas signific impact
success integr prior join
compani blazejewski senior vice presid
presid global patient monitor recoveri pmr
busi blazejewski nearli year sale
market execut leadership experi within
medic devic industri tenur patient
recoveri busi evolv root sherwood
medic chang tyco healthcar covidien
craig cowman execut vice presid global sourc
manag strateg sourc supplier manag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
compani also held executive-level
commerci clinic role sunesi corpor
dendreon corpor imclon incorpor abraxi
overal leader season divers
background pharmaceut distribut see
enterprisewid capac lead team
respons sourc pharmaceut medic
product across nation brand cardin brand
well raw materi indirect good prior assum
role cowman serv compani senior vice
presid strateg sourc product manag
respons develop
deploy cardin health brand gener
consum health sourc price sell strategi
pharmaceut segment cowman
year develop
wide rang manag experi perspect
varieti area within cardin health includ
market sale telesal purchas
victor crawford chief execut offic
pharmaceut segment segment
distribut brand gener pharmaceut specialti
pharmaceut over-the-count healthcar
consum product crawford came
wide rang experi world
respect compani recent role
chief oper offic healthcar
educ busi dine join
crawford serv presid field oper
pepsi-cola beverag compani guid field leadership
team canada mexico initi join
pepsi-cola bottl compani work
varieti role financ sale appoint
vice presid gener manag greater
chicago divis pepsi-cola gener bottler inc
depinto presid cardin health specialti
solut one fastest-grow busi cardin
depinto spent past year focus
commerci specialti drug market past role
includ sale market leadership posit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
opioid litig overhang continu exert pain
drug manufactur distributor aug
across thousand civil case mostli
state court repres state prosecutor
compens famili hurt opioid
epidem plaintiff case accus drug
manufactur activ market addict drug
pharmaceut distributor fail detect/report
suspici opioid order mani defend
case gener drug manufactur pharmaceut
distributor retail pharmaci coverag
three pharmaceut distributor coverag
handl roughli drug dispens across
countri sophist infrastructur allow
track manag suppli logist drug
result key role distributor track drug
provid copi drug order drug enforc
administr histor role requir
polic opioid civil suit distributor
accus market profit distribut
opioid prosecut team alleg distributor
alert suspici spike opioid
volum step requir report
walgreen includ group compani
gener sourc joint ventur quarter
equiti stake
consider specul distributor activ
discuss prosecutor propos financi
settlement rang billion
distributor distributor like abl absorb
propos fine long spread multipl
first opioid case settl purdu
agre justic depart fine million
intens market push brand opioid drug
oxycontin subsequ purdu also settl
state washington charg over-
prescript oxycontin year
least eight state feder opioid settlement
defend agre pay larg fine
million
purdu million case settl aggreg
nearli billion span
recent financi demand acceler
fuel polit social activist advoc
compani compens famili impact opioid
crisi recent civil case settlement sum
loom billion local oklahoma court
purdu teva reach court settlement
million million respect aug
oklahoma judg rule johnson johnson fine
million compani plan appeal feder
court result abus discret local
oklahoma judg elect offici understand
purdu teva settl court avoid
potenti neg sway onto significantli larger feder
case pend ohio hit hardest addit
oklahoma case two gener drug manufactur
defens endo allergan settl ohio million
million respect reckitt benckis also agre
settl govern billion
billion cumul settlement
settl decid opioid case financi
crippl defend includ legal fee
mount defens instanc estim
unlik prior civil case feder court ohio
propos consolid roughli civil case
across multipl district approxim
opioid case countri trial schedul kick
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
oct consider leak propos term
suggest activ settlement negoti
play continu exert signific pressur relev
healthcar stock like impetu settl
consolid case eerili similar landmark
multi district litig mdl creat
relat civil person injuri wrong
death case asbesto manufactur notabl john
manvil mdl case tri en mass behalf
plaintiff similarli situat feder level
due larg number parti involv civil trial
schedul occur multipl track overal
defend anticip feder court neutral
venu rel local court run judg
special interest collect largest fine
drug manufactur distributor improv re-elect
aspir although activ negoti ohio behind
close door unidentifi sourc indic
purdu may explor unpreced
billion settlement decept market well-
known opioid painkil oxycontin purdu case
front center activ market brand opioid
aggreg revenu billion
asbesto mdl defend file bankruptci
protect strategi purdu may may
manufactur opioid pill distribut
time frame although opioid pill count
purdu rel lower manufactur
list prosecut appear aggress target
purdu opioid drug brand heavili
market drug manufactur spend signific dollar
market brand drug like crux civil
case unlik brand drug gener significantli
cheaper formul sold base price
activ market result case gener
manufactur produc larger quantiti
like penal heavili peer brand
opioid view
second largest distributor
grow faster peer indic
distributor fourth largest
volum opioid prescript period
billion pill amerisourc distribut partner
walgreen estim second largest opioid
distributor billion pill amerisourc growth
larg driven larger exposur specialti drug
improv sell-through servic walgreen
amerisourcebergen oper hinder
remedi cost compound busi acquir
continu success specialti like
mask drag next five year forecast
cash flow billion
mani defend opioid litig
attent event transpir ohio prepar
respect defens base figur present
drug enforc administr purdu pharma
manufactur opioid pill
unlik larger peer compani activ market
brand drug teva manufactur opioid
pill distribut throughout countri time
period actavi pharma compani teva acquir
cardin health smallest distributor growth
driven increas specialti mix compani
hinder integr prior acquisit especi
contract manufactur commod medic devic
indic distributor
third largest volum opioid pill billion
model free cash flow billion next sever
year aug compani file prospectu
sec unidentifi mix shelf offer common
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
prefer debt secur suspect file
pre-empt need fund propos opioid litig
largest distributor continu
challeng canada segment result
anticip compani grow slightli slower
peer compani least leverag forecast
gener largest free cash flow next five year
billion indic
distributor largest volum opioid pill billion
multipl put take net better-than-expect
result think unchang
narrow moat cardin report quarterli result
solid gener ahead expect
share compani highlight sub-seg
key driver growth quarter also consist note
peer cardin health smallest three
environ like squeez retail custom
gener manufactur maintain fair valu
estim narrow moat rate share trade slightli
higher intra-day compani
high reflect disadvantag
market posit rel two larger peer recent
manag shuffl view
trade less high
distribut stronger expect
increment mileston met cost save
medic segment price pressur recent
contract renew largest custom
third quarter fourth quarter gener
price pressur appear contradictori peer
like reflect compani rel smaller size
revenu growth larg driven stronger-than-
expect specialti revenu growth lesser degre
improv mix skew toward brand drug
earn benefit better-than-expect tax rate
realiz cost save initi somewhat dampen
slower expect turnaround medic segment
impli mid-single-digit overal revenu
growth net declin margin midpoint fiscal
guidanc approxim fiscal result well
fiscal non-gaap ep
cardin cfo departur like reflect
announc jorg gomez resign
cfo vacat posit aug day
schedul releas fourth-quart result
cfo head cardin ceo
serv interim cfo perman replac
secur announc follow recent revis
narrow moat rate neg bia reflect
swell pressur competit landscap
price
although three largest distributor secur
market cardin smallest despit
increas opioid litig pressur weak market
posit
current
infrastructur may neg affect compani abil
differenti win pure base price cardin
challeng integr cordi recent medic devic
manufactur acquisit may also contributor
distributor within
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
narrow rang less
upsid quarter compani also
renew contract largest custom
account fiscal revenu concern
price medic segment perform potenti
fiscal third-quart revenu grew year year
billion normal ep increas year
year pharmaceut distribut revenu
increas driven specialti pharmaceut volum
slightli off-set headwind gener
medic revenu declin prior quarter
recent pharmaceut market growth slow
significantli double-digit growth observ
year ago distributor larg compens
percentag revenu aggress use
price poach client cardin loss walgreen
pharmaci market year ago probabl
largest casualti distributor also challeng
differenti sought growth
anem market acquisit outsid core
oper distributor stumbl integr
acquisit cardin health challeng
integr cordi aggress ration
product offer exit countri expect
compani report fourth-quart non-gaap earn per
share aug fiscal closer
high end full-year guidanc
strong quarter despit weak
report quarterli result exceed
expect driven distribut growth notabl
progress cost save initi consist note
peer specialti revenu continu key driver
growth pharmaceut spend distribut
distribut stronger expect stride
made cost save initi sever
offset includ weaker-than-expect growth
oper execut medic segment neg
impact gener program perform impact
prior custom renew opioid litig expens
share flat intra-day seem appropri
lack transpar fiscal lack clariti around
gener price seem contradictori peer
comment gener price stabil maintain
fair valu estim narrow moat rate
manag rais bottom end full-year guidanc
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end june
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
